Is double-blinding achievable in a placebo-controlled trial with the glucagon-like-peptide-1 receptor agonist liraglutide?

S. Foghsgaard; L. Vedtofte; E. Bahne; C. Andreasen; L. K. Christiansen; J. A. Svare; T. D. Clausen; E. R. Mathiesen; P. Damm; L. L. Gluud; F. K. Knop; T. Vilsboll

Is double-blinding achievable in a placebo-controlled trial with the glucagon-like-peptide-1 receptor agonist liraglutide?

S. Foghsgaard, L. Vedtofte, E. Bahne, C. Andreasen, L. K. Christiansen, J. A. Svare, T. D. Clausen, E. R. Mathiesen, P. Damm, L. L. Gluud, F. K. Knop, T. Vilsboll

Institut for Klinisk Medicin

Originalsprog	Engelsk
Tidsskrift	Diabetologia
Vol/bind	60
Sider (fra-til)	S369-S369
ISSN	0012-186X
Status	Udgivet - 2017

Citationsformater

@article{9d8209793bb848ae81db5e7c444931a0,

title = "Is double-blinding achievable in a placebo-controlled trial with the glucagon-like-peptide-1 receptor agonist liraglutide?",

author = "S. Foghsgaard and L. Vedtofte and E. Bahne and C. Andreasen and Christiansen, {L. K.} and Svare, {J. A.} and Clausen, {T. D.} and Mathiesen, {E. R.} and P. Damm and Gluud, {L. L.} and Knop, {F. K.} and T. Vilsboll",

year = "2017",

language = "English",

volume = "60",

pages = "S369--S369",

journal = "Diabetologia",